ADMA BIOLOGICS, INC. Deferred Income Tax Expense (Benefit)
ADMA BIOLOGICS, INC. (ADMA) reported Deferred Income Tax Expense (Benefit) of $3.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-05
- ADMA BIOLOGICS, INC. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $3.00K, a 99.81% decline year-over-year.
- ADMA BIOLOGICS, INC. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $3.29M, a 3.88% decline year-over-year.
- ADMA BIOLOGICS, INC. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $1.17M.
- ADMA BIOLOGICS, INC. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was $4.80M.
- ADMA BIOLOGICS, INC. deferred income tax expense (benefit) for fiscal 2025 was $11.02M.
- ADMA BIOLOGICS, INC. deferred income tax expense (benefit) for fiscal 2024 was -$84.28M.
- ADMA BIOLOGICS, INC. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- ADMA BIOLOGICS, INC. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.29M 10-Q · filed 2026-08-05 | $4.47M derived: sum of 3 quarters · filed 2026-08-05 | $9.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.29M 10-Q · filed 2026-05-06 | $4.46M derived: sum of 2 quarters · filed 2026-05-06 | $9.27M derived: sum of 3 quarters · filed 2026-05-06 | $10.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.97M derived: sum of 2 quarters · filed 2026-02-25 | $7.59M derived: sum of 3 quarters · filed 2026-08-05 | $11.02M 10-K · filed 2026-02-25 |
| 2025-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.42M derived: sum of 2 quarters · filed 2026-08-05 | $9.85M 10-Q · filed 2025-11-05 | -$74.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.04M 10-Q · filed 2026-08-05 | -$79.23M derived: sum of 3 quarters · filed 2026-08-05 | -$79.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.42M 10-Q · filed 2026-05-06 | -$80.86M derived: sum of 2 quarters · filed 2026-05-06 | -$80.86M derived: sum of 3 quarters · filed 2026-05-06 | -$80.86M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$84.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$84.28M derived: sum of 2 quarters · filed 2026-02-25 | -$84.28M derived: sum of 3 quarters · filed 2026-02-25 | -$84.28M 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |